80
Participants
Start Date
June 30, 2013
Primary Completion Date
February 29, 2016
Study Completion Date
June 30, 2016
Civacir® 10%
The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.
NYU Langone Medical Center, New York
The Mount Sinai Medical Center, New York
Columbia University College of Physicians and Surgeons, New York
University of Virginia Health System, Charlottesville
Piedmont Hospital, Atlanta
Emory University School of Medicine, Atlanta
Florida Hospital Transplant Institute, Orlando
University of Miami Miller School of Medicine, Miami
Vanderbilt University Medical Center, Nashville
Methodist University Hospital, Memphis
University of Kentucky Chandler Medical Center, Lexington
Northwestern Memorial Hospital, Chicago
Ochsner Medical Center, New Orleans
Baylor University Medical Center, Dallas
Advanced Liver Therapies / St. Luke's Episcopal Hospital, Houston
Houston Methodist Hospital, Houston
Houston Methodist, Houston
University of Utah Health Sciences Center, Salt Lake City
University of Southern California / Keck Hospital, Los Angeles
University of California San Francisco, San Francisco
Oregon Health & Science University, Portland
Beth Israel Deaconess Medical Center, Boston
Lahey Hospital, Burlington
Lead Sponsor
Biotest Pharmaceuticals Corporation
INDUSTRY